In a significant move aimed at enhancing treatment options for serious mental illnesses, President Trump has signed an executive order to expedite research and access to psychedelic drugs, including controversial substances like ibogaine, psilocybin, and LSD. The order directs the FDA to fast-track their review process, particularly for treatments related to PTSD and other mental health conditions. This initiative is part of broader reforms to loosen restrictions on psychedelics and urges increased research into their therapeutic potential. The announcement has garnered attention from various stakeholders, including mental health advocates and researchers, who see this as a pivotal step in integrating psychedelic therapies into conventional medical practices.